Second Balkan Conference on Personalized Medicine: ProgramЖасмина Коева
Second Balkan Conference on Personalized Medicine
October 24th-25th, 2019, “Opal”Hall, Hotel “Ramada”, Sofia
Organized by the Bulgarian Alliance for Precision and Personalized Medicine – BAPPM
In collaboration with the European Alliance for Personalised Medicine – EAPM, Medical University Pleven and Bulgarian Society of Human Genetics and Genomics
Thursday, October 24th, 2019
13.30 – 14.00 Registration
14.00 – 14.30 Opening: Setting the Scene
Dr. Jasmina Koeva, Chair of the Board, BAPPM
Denis Horgan, Executive Director EAPM
Keynote opening speech: Maria Gabriel – European Commissioner for Digital Economy and Society
Discussion with European Commissioner
14.30 – 16.00 First Plenary Session: Forward Together in the Personalised Medicine Era
Personalized Medicine – What will be covered in this opening session is the broad impact of the personalized medicine, which promises to create a new paradigm in healthcare.
The key is to find the optimum ways by which to integration personalized medicine into the EU’s healthcare systems, facilitate, the introduction of innovative pharmaceuticals and diagnostics, and build the necessary legal and regulatory frames.
In addition, there is a need to formulate optimal HTA of personalized medicine products, and, of course, bring about the best pathways to dramatically improve patient access to innovative treatments
Chair of session and Scene Setting: Denis Horgan, Executive Director EAPM
Karina Angelieva – Deputy Minister of Education and Science, Bulgaria:”Bulgaria on the European Map of Personalised Medicine – BBMRI, EATRIS, Centers of Excellence and Centres of Competence, National Research Programme”
Dr. Tuula Helander – Finnish Presidency of European Council, Ministry of Social Affairs and Health, Finland
Ass. prof. dr. Lachezar Ivanov – Vice-chair of Health Commission in the Parliament of Bulgaria – invited
Dr. Jana Makedonska, Policy Officer, Unit for Health Innovations, DG Research & Innovation, European Commission: “European support for international cooperation in personalised medicine”
16.00 – 17.40 Second Plenary Session: Genomics for Healthcare
This session will look at new achievements in human genomics and genetics alongside gene therapy and the European Genomic Initiative “1+MG”.
With rising healthcare costs and systems being increasingly challenged, genomics has the potential to impact the health of all of us and provide diagnostic, economic and efficiency benefits, ensuring a patient has the right information, to get the right treatment, at the right time.
The potential for bettering the health of citizens across all Member States is huge.
If fully realized genomics will have a positive impact on the health of all of us by giving diagnostic, economic and efficiency benefits by ensuring the right patient, gets the right diagnosis and treatment, at the right time. Also hugely important for healthcare (and fiscal) reasons is the preventative sector which involves screening and early diagnosis, while the session will also include the important areas of rare diseases, oncology and neurological diseases.
Precision diagnostics are vital today, so we will look at NGS in preventive medicine and clinical practice. Comprehensive genomic profiling will also be discussed.
On top of this, the growing area of AI in personalized medicine cannot be denied, but implementing it is a key. Here we look at the current status and future possibilities.
Session chair: Prof. Dr. Draga Toncheva – President of Bulgarian Scientific Society for Human Genomics and Genetics
Setting the Scene: Dr. Jasmina Koeva-Balabanova, Chair of BAPPM: “1+ MG”Initiative
Prof. Dr. Borut Peterlin, Head of the Clinical Institute of Medical Genetics, Ljubljana, Slovenia: “Public health genomics: lessons from rare diseases”
Dr. Radoslav Mangaldjiev – Chair of Society of Medical Oncologists, Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria: “The Advantage of Foundation Medicine-Comprehensive Genomic Profiling in clinical Practice”
Hari Radhakrishnan, Chief Business Development Officer at NIPD Genetics, Cyprus: “Next-generation oncology panels for detailed analysis of cancer genes”
Prof. Dr. Draga Toncheva, President of Bulgarian Scientific Society for Human Genomics and Genetics: “Medical genetic counseling and risk assessment for hereditary prostate cancer”
17.40 – 18.00 Coffee-break
18.00 – 19.10 Third Plenary Session: The pathology of Personalised Medicine
Molecular pathology – specifically new achievements and implementation in clinical practice.
Precision imaging in modern-day healthcare.
Session chair: Prof. dr. Savelina Popovska – Vice-rector Medical University Pleven, Bulgaria
Prof. Dr. George J Netto, Chair of Department of Clinical Pathology, University of Alabama at Birmingham, USA: “Molecular Pathology – opportunities and challenges”
Prof. Sven Seiwerth – Head of Department of Pathology, University of Zagreb, Croatia: “Predictive biomarker testing in Croatia“
Prof. Dr. Sonya Sergieva-Chief of Department “Nuclear Medicine”, Specialized Hospital in Active Treatment in Oncology, Sofia, Bulgaria: “Teranostica – current nuclear medicine diagnostic and therapeutic approach for personalized treatment of neuroendocrine tumors“
19.30 – 22.00 Official Dinner and announcement of the winners of BAPPM Awards for Personalized Medicine in Bulgaria
Host: Dr. Jasmina Koeva-Balabanova, Chair of the Board of BAPPM
Friday, October 25th, 2019
08.30 – 09.0 Registration and Morning Coffee
09.00 – 12.00 Fourth Plenary Session: Personalized medicine in oncology
This session will cover screening, targeted and combined therapy, as well as adjuvant and neoadjuvant therapy.
Also covered will be immunotherapy, radiotherapy, the monitoring of lung cancer, as well as breast cancer, colon cancer, prostate cancer, melanoma, pancreatic cancer, and head and neck cancer.
However, as always, we should be aware of the economic impacts (good and bad) of precision medicine. An outstanding high cost will not be sustainable in the long term, so development of technologies for cost reduction should not be ignored
Chair: Antoni Monserrat Moliner – Active Senior on Public Health for the European Commission
09.00-10.20 Guidelines and Best Practices
Ciaran Nicholl, Joint Research Center Ispra, European Commission: ”Evidence-based European Guidelines for quality assured, patient-centric cancer health care”
Beata Jagielska, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Department of Oncological Diagnostic, Cardio-Oncology and Palliative Care, Warsaw, Poland: “Value Based Healthcare as challenge for innovative medicine”
Dr. Rositza Krasteva – Head of Oncology Center/Comprehensive Cancer Care/ and Medical Oncology Department, “UniHospital”, Panayurishte, Bulgaria:”Personalised Cancer Therapy”
10.20 – 10.40 Networking Break
10.40 – 12.00 Early Diagnosis and Screening – new technologies and personalization
Chair: Dr. Rositza Krasteva – Head of Oncology Center “UniHospital”, Panayurishte, Bulgaria
Prof. Dr. George Momekov-Chairman of Bulgarian Scientific Pharmaceutical Society, Bulgaria: ”Advanced Prostate Cancer – personalized approach”
Dr. Alexander Simidchiev-Chief of Department of Functional Diagnostics, Medical Institute of the Ministry of Interior, Bulgaria: ”A dose of screening – personalising prophylaxis“
Prof. Dr. Sonya Sergieva-Chief of Department “Nuclear Medicine”, Specialized Hospital in Active Treatment in Oncology, Sofia, Bulgaria: ”Nuclear medicine methods for individualized diagnostics and therapy of thyroid cancer“
12.00-13.00 Working Lunch
13.00 – 14.50 Fifth Plenary Session: Personalized medicine and rare diseases, neurology and psychiatry
Some of the bottlenecks for precision medicine include the cost, as well as privacy concerns. These designer drugs are usually only effective for a small cohort of patients, so to recover costs put into developing the drug, a pharmaceutical company may charge much higher prices than for other medicines.
Also, like other health data, genetic information is private information, so security must be maintained for all patients.
For neurological diseases there is a need for comprehensive genetic assessment, classification, biomarkers, and treatments specified to a person’s molecular drivers.
This session will cover these topics and more.
Chair of session: Antoni Monserrat Moliner – Luxembourg National Committee for Rare Diseases
Setting the Scene:
Ciaran Nicholl, Joint Research Center Ispra, European Commission: ”New European Platform on Rare Disease Registration”
Prof. Dr. Rumen Stefanov – Director of “Institute for Rare Diseases”, Bulgaria: “Challenges for improving access to innovative medicinal therapies”
Dr. Petja Stratieva – Development Executive Central and Eastern Europe “Retina International”: „Equitable access to therapies for rare diseases: the patient perspective“
Prof. Dr. Ara Garabed Kaprelyan – Head of Department of Neurology and Neuroscience, Medical University Varna, Bulgaria:”Personalised Medicine and cutting-edge nanotechnologies in CNS diseases”
Ass. Prof. Dr. Diana Pendicheva – Medical University Pleven, Bulgaria: „What’s new beyond Genome-Wide Association Studies in Pharmacogenomics of Affective Disorders?“
14.50 – 15.30 Sixth Plenary Session: Cooperation & Balkan Framework
No Member State can go it alone when it comes to modern-day healthcare, despite the closely guarded national competence in this large arena.
Cross-border collaboration is vital now and will be even more so going forward, and the innovative work of regions must also be harnessed and, crucially, shared.
This final session will seek to establish the need for cooperation and seek a unity that such cooperation is necessary as we strive to make personalised medicine the norm, and deliver the right treatment to the right patient at the right time.
Chair of session: Jasmina Koeva-Balabanova, Chair of the Board, BAPPM, Bulgaria
Denis Horgan – Executive Director, EAPM
Representatives of participatory countries
15.30 – 16.00 Poster Session
Chair of Session: Prof. Dr. George Christoff, Medical University Sofia, Bulgaria
16.00 – 16.15 Closing
Application for poster sessions: firstname.lastname@example.org
Official languages: Bulgarian and English
Лектори, потвърдили участие:
European Commissioner for Digital Economy and Society
Dr. Tuula Helander
Finnish Presidency of European Council, Ministry of Social Affairs and Health, Secretary General, Finnish Cancer Institute
RTD, European Commission, Policy and Research Program Officer – Health Research
Chief Business Development Officer at NIPD Genetics, Nicosia, Cyprus
Prof. Dr. Sonya Sergieva
Chief of Department “Nuclear Medicine”, Specialized Hospital in Active Treatment in Oncology, Sofia, Bulgaria
Prof. George Momekov
Chairman of Scientific Pharmeceutical Society, Bulgaria
Dr. Petja Stratieva
Development Executive Central and Eastern Europe “Retina International”
Dr. Jasmina Koeva-Balabanova
Chair of the Board, BAPPM
Prof. Dr. Draga Toncheva
President of Scientific Society of Human Genomics and Genetics, Bulgaria
Prof. Dr. Savelina Popovska
Vice-Rector, Medical University, Pleven, Bulgaria
Antoni Monserrat Moliner
Active Senior on Public Health for the European Commission, Member of the Luxembourg National Committee for Rare Diseases
Dr. Rositza Krasteva
Head of Oncology Center “Unihospital”/Comprehesive Cancer Care/ and Medical Oncology Department, Panagjurishte, Chairman of “Young Oncologist” Club, Bulgaria
Ass. Prof. Dr. Diana Pendicheva-Duhlenska
Medical University Pleven, Bulgaria
EAPM Executive Director
Prof. Dr. Borut Peterlin
Clinical Institute of Medical Genetics, University Medical Center, Ljubljana, Slovenia
Prof. Dr. George J Netto
Chairman of Department of Clinical Pathology, University of Alabama at Birminhgam, USA
Joint Reseach Center, Ispra, European Commission
Dr. Alexander Simidchiev
Chief of Department of Functional Diagnostics, Medical Institute of the Ministry of Interior, Bulgaria
Prof. Dr. Ara Kaprelyan
Head of Department of Neurology and Neurosciense, Medical University Varna
Deputy Minister of Education and Science, Bulgaria
Dr. Radoslav Mangaldjiev
Chair of Society of Medical Oncologists, Chief of Department of Medical Oncology, Specialized Hospital of Active Treatment in Oncology, Sofia, Bulgaria
Prof. Dr. Sven Seiwerth
Head of Institute of Pathology, Medical School, University of Zagreb, Croatia
Dr. Beata Jagielska
Deputy Director Scientific Institute of Oncology “Maria Sklodovska-Curie”, Warsaw, President of Polish Alliance for Personalised Medicine, Poland
Prof. Dr. Rumen Stefanov
Director of Institue of Rare Diseases, Bulgaria
Prof. dr. George Christoff
Faculty of Public Health, Medical University Sofia, Bulgaria